

Cover Story
Conversation with The Cancer LetterFree
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
In Brief
Clinical Roundup
NCI Trials


NCI trials for February
NCI trials for FebruaryThe National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Cancer Research Institute announces 2025 recipients of cancer immunotherapy awards
- USPSTF doesn’t lean right or left—it’s about data, not politics
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts